During a day at his office, I saw three patients who’d had success with CBD. The first was Sawyer Maddox, five, from Atlanta, who’d been diagnosed at three with a rare form of epilepsy, Doose Syndrome, which is resistant to medication. He was having more than 200 seizures a day, where he’d drop face first on the floor. His parents fitted him with a catcher’s mask for protection, and carpeted their home with foam to cushion his falls. The pediatric neurologist they saw in Atlanta gave him meds that made things worse. Desperate, the Maddoxes, a conservative Baptist family, flew to California to see Frankel. He started Sawyer on #1 oil, and three months later, the boy was seizure free.
He did exhaustive research. He found there’d been decades of scientific studies on the effects of THC and CBD on cells and animals, but few trials with humans, because the FDA classifies cannabis and all its components as Schedule 1 drugs, which have “no accepted medical treatment use.” It took Sue Sisley, an Arizona physician, seven years of struggling with bureaucratic hurdles before she received the first FDA approval for a study, just beginning, of marijuana with vets who have PTSD.
When the endocannabinoid system becomes dysregulated, it often becomes overactive and too much fat is being stored, particularly in the intra-abdominal tissue. Cannabidiol is known to regulate the endocannabinoid system as it can restore balance in both directions. Therefore, the study concludes that, along with lifestyle changes cannabis could be a means of fighting obesity.